On August 6, 2025, MetaVia, Inc. (NASDAQ:MTVA) announced that the company has extended the 48 mg multiple ascending dose (MAD) cohort of the Phase 1 clinical trial of DA-1726, the company’s ...
In November 2025, MetaVia, Inc. (NASDAQ:MTVA) announced new data from the Phase 2a clinical trial of vanoglipel (DA-1241) was presented in a poster session at the American Association for the Study of ...
The average one-year price target for MetaVia (NasdaqCM:MTVA) has been revised to $19.72 / share. This is a decrease of 71.04% from the prior estimate of $68.08 dated April 12, 2026. The price target ...
The average one-year price target for MetaVia (NasdaqCM:MTVA) has been revised to $159.88 / share. This is an increase of 1,000.00% from the prior estimate of $14.54 dated November 14, 2025. The price ...
Short interest in MetaVia Inc (NASDAQ:MTVA) decreased during the last reporting period, falling from 198.09K to 60.60K. This put 6.38% of the company's publicly available shares short. Based on the ...
Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results